Intellia Therapeutics (NTLA) PT Raised to $252 at Goldman Sachs
Tweet
Share
E-mailGet Alerts NTLA Hot Sheet
Price: $11.91 +0.68%
Rating Summary:
23 Buy, 9 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
23 Buy, 9 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Goldman Sachs analyst Salveen Richter raised the price target on Intellia Therapeutics (NASDAQ: NTLA) to $252.00 (from $225.00) while maintaining a Buy rating.
You May Also Be Interested In
- Keefe, Bruyette & Woods Downgrades Bain Capital Specialty Finance (BCSF) to Market Perform
- CMC Markets (CMCX:LN) (CCMMF) PT Raised to GBP7.60 at RBC Capital
- Astellas Pharma Inc (4503:JP) (ALPMY) PT Raised to JPY2,500 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
